GSK heart drug disappoints

Investor's Business Daily
November 2013
Investors Business Daily;11/13/2013, pA02
A heart drug


Related Articles

  • Effects of Early Blood Pressure Lowering on Early and Long-Term Outcomes after Acute Stroke: An Updated Meta-Analysis. Wang, Hongxuan; Tang, Yamei; Rong, Xiaoming; Li, Hui; Pan, Rui; Wang, Yidong; Peng, Ying // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Background: Hypertension is common after acute stroke onset. Previous studies showed controversial effects of early blood pressure (BP) lowering on stroke outcomes. The aim of this study is to assess the effects of early BP lowering on early and long-term outcomes after acute stroke. Methods: A...

  • One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Hansteen, V.; Moinichen, E.; Lorentsen, E.; Strom, O.; Soiland, K.; Dyrbekk, D.; Refsum, A.-M.; Tromsdal, A.; Knudsen, K.; Eika, C.; Jun, J. Bakken; Smith, P.; Hoff, P.I. // British Medical Journal (Clinical Research Edition);1/16/1982, Vol. 284 Issue 6310, p155 

    Investigates the effects of propranolol and placebo on patients with history of myocardial infarction in Norway. Rate of mortality; Reduction in sudden cardiac deaths among high risk patients treated with propanol; Benefits of long-term beta-adrenoceptor blockade in low-risk patients.

  • GSK and HOS put the 'us' in lupus. Comer, Ben // Medical Marketing & Media;Mar2011, Vol. 46 Issue 3, p22 

    The article offers brief information on Glaxosmithkline (GSK) and Human Genome Sciences Inc.'s (HGS) lupus website.

  • Looking for the Reward, Living with the Risk.  // Bioworld Week;5/2/2011, Vol. 19 Issue 18, p5 

    The article focuses on the preparation of Human Genome Sciences Inc. and partner GlaxoSmithKline plc to launch their anti-systemic lupus erythematosus (SLE) drug Benlysta, which has been approved by the U.S. Food and Drug Administration (FDA) on March 9, 2011, 56 years after the agency had...

  • Long term propranolol treatment and changes in body weight after myocardial infarction. Rossner, Stephen; Taylor, Carol L.; Byington, Robert P.; Furberg, Curt D. // BMJ: British Medical Journal (International Edition);4/7/90, Vol. 300 Issue 6729, p902 

    Examines the effect of long term propranol treatment and changes in the body weight after myocardial infarction. Analysis of placebo controlled data; Changes in the body weight; Implication in diuretics or physical activity.

  • Human Genome Returning 13% with Bet on Glaxo Sweetener.  // MondayMorning;6/18/2012, Vol. 20 Issue 24, p1 

    The article reports that the investors of Rockville, Maryland-Based Human Genome Sciences Inc. bet on a bid from GlaxoSmithKline Plc to produce 13 percent rate of return. According to WallachBeth Capital LLC and Piper Jaffray Cos., Galxo may raise its bid to 15 dollar a share to overcome the...

  • Today's Transactions: Glaxo Wins HGS After Upping Price. NOTO, ANTHONY // Mergers & Acquisitions Report;7/23/2012, Vol. 25 Issue 30, p3 

    The article reports on the expected acquisition by pharmaceutical company GlaxoSmithKline plc of biotechnology firm Human Genome Sciences Inc. (HGS) for roughly 3.6 billion U.S. dollars.

  • Glaxo making offer for genome firm.  // Indianapolis Business Journal;5/14/2012, Vol. 33 Issue 11, p17 

    The article reports on the plans of GlaxoSmithKline PLC to initiate a hostile 2.6 billion dollars tender offer for Human Genome Sciences Inc. after the latter rebuffed a takeover approach.

  • BENLYSTA.  // MPR - Residents' Edition;Spring/Summer2011, Vol. 20 Issue 1, pA.6 

    The article offers brief information on the monoclonal antibody drug Benlysta, which is indicated for the treatment of systemic lupus erythematosus in adults, from Human Genome Sciences Inc. and GlaxoSmithKline.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics